J. Bernadette Moore and James L. Thorne N on-alcoholic fatty liver disease (NAFLD) is a complex phenotype that results from interactions between genetic, dietary, and lifestyle factors 1 . Closely associated with obesity, NAFLD is now an important public health concern worldwide, with approximately 25-30% and 5% of the general population in many countries having fatty liver (steatosis) or clinically meaningful fibrosis, respectively. Although several genetic variants that influence susceptibility to NAFLD as well as liver disease more generally have been identified, these variants do not account for all of the estimated heritability of liver fat and fibrosis 1 . NAFLD is challenging to diagnose and treat and there are unmet clinical and public health needs for non-invasive biomarkers for the disease. A critical research question is how to predict who is at significantly higher risk of developing hepatic lipotoxicity and advanced liver disease.
Capitalising on a genetic reference panel of 107 inbred mouse strains, a new study has taken a systems biology approach integrating plasma and liver lipidomics with proteomics and quantitative trait loci (QTL) mapping, which allows the predictions of genetic variants involved in hepatic lipotoxicity 2 . Using 2-3 replicate male mice, aged approximately 60 days, from Hybrid Mouse Diversity Panel (HMDP) strains that exhibit substantial diversity in metabolic traits relevant to human disease, Parker and colleagues integrate systems genetics and correlation analyses to identify genetic variants and co-regulated networks that influence hepatic proteome and lipidome abundance across the HMDP (Fig. 1a) . This work makes several important contributions to the field by identifying novel lipid-regulatory proteins, as well as novel candidate circulating biomarkers for improving diagnosis and determining prognosis in liver disease.
The paper exploits the significant interstrain variation for both liver and plasma lipid abundance, with triacylglycerol levels in liver and plasma, for example, varying by 27-fold and 16-fold, respectively. Correlation analyses between 190 plasma and liver lipid species, in combination with machine learning models, were used to identify plasma lipid signatures that had high predictability for the abundance of hepatic lipids associated with pathology (such as ceramides, diacylglycerol and triacylglycerol). Notably, two signatures of plasma lipid ratios were found to correlate with human liver triacylglycerol and diacylglycerol levels in a cohort of 58 patients with obesity and with hepatic steatosis. Integration of QTL mapping for hepatic protein (pQTLs), plasma and hepatic lipid (lQTLs), and protein:lipid correlation data identified 281 single nucleotide polymorphisms mapping to 17 genetic loci that contained a pQTL, an lQTL, and a direct correlation between the mapped protein and lipid in the liver. For example, the GLO1 locus was identified as having both a significant cis-pQTL and having lQTLs for multiple hepatic triacylglycerol species, whereas the glyoxalase 1 (GLO1) protein correlated with 9 triacylglycerol species in the liver (Fig. 1b) . These data corroborate the results of Spanos and colleagues, who had, through proteomic screening, previously identified altered hepatic GLO1 expression, which they confirmed in paediatric patients with NAFLD 3 . This independent finding further implicates GLO1 disruption as a causative factor in hepatic lipotoxicity and cardiometabolic disease. Targeting GLO1 remains largely unexplored in the therapeutic setting. Although initial results from a pilot clinical trial of a glyoxalase 1 inducer (a combination of the dietary bioactive compounds trans-resveratrol and hesperetin) in 29 participants who were overweight or obese suggested that GLO1 induction improved glycaemic control, insulin resistance and vascular function 4 . Global correlations between the lipidomic and proteomic datasets, in combination with pathway enrichment, identified proteins associated with the proteasome and proteolysis as strongly correlated with hepatic lipid abundance. The authors followed up on 26S proteasome non-ATPase regulatory subunit 9 (PSMD9, also known as p27), a relatively unstudied protein that strongly correlated with multiple hepatic and plasma lipid species. PSMD9, a proteosomal chaperone protein, is released during assembly of the 26S proteasome 5 . Intriguingly, PSMD9 has previously been associated with changes in lipid droplet composition under conditions of caloric restriction and intermittent fasting 6 . Early work suggested that PSMD9 also has transactivating activity influencing glucose-dependent insulin production and glucose metabolism 7 . Parker and colleagues identified a significant cispQTL within the PSMD9 locus that also co-mapped to multiple lQTLs for plasma triacylglycerols. In an impressive proof-ofconcept work, the authors used antisense oligonucleotides to silence PSMD9 in two strains of mice (DBA/2J and C57BL/6J) that vary significantly in abundance of liver and plasma lipids and were fed a western diet for 28 days. Silencing of PSMD9 reduced plasma lipids and prevented hepatic steatosis preferentially in DBA/2J mice, partly through reductions in fatty acid synthesis by de novo lipogenesis.
Strengths of this work include the integration of intermediate phenotypes (proteomics and lipidomics) with the highresolution genomic association mapping of HDMP and the examination of plasma and liver lipid abundance as quantitative traits. Quantifying >4,000 proteins in more than 50 strains of mice along with 311 lipid species across 3 classes is not a trivial experimental accomplishment, and the associated datasets of this study are a rich bioinformatics resource. Exploitation of the high inter-strain differences in lipid traits observed within the HDMP was a key strength; without such variation, the associated genetic variant loci would not have been identified. The authors rationally targeted their investigation a priori to a subset of known pathogenic lipid subclasses, and then again to those that were most strongly correlated (ceramides, triacylglycerols, and diacylglycerols). Nonetheless, other pathogenic lipid profiles might be present in the liver, along with associated plasma signatures, and the application of unsupervised data-centric approaches could help their identification. Similarly, whereas the authors followed up on PSMD9 and highlighted the independent GLO1 data, other loci identified could also be worth detailed investigation, in particular how they translate to human disease. Notably, the enzyme serine hydroxymethyltransferase, cytosolic (SHMT1), was also among the loci identified that have a pQTL, lQTL and correlation between protein and lipid in the liver. Previous systems approaches using a genome-scale metabolic network in tandem with transcriptomic data from patients with NAFLD revealed a serine deficiency in NAFLD and proposed SHMT1 as possible target 8 .
A key question will be how these results translate to human disease. The differential effect of PSMD9 knockdown observed in the DBA/2J and C57BL/6J strains underscores caution that a single target for NAFLD is likely to suffice. There are, and will be further, genetic and environmental mediators of hepatic lipotoxicity, particularly in outbred humans. Only male animals were profiled in this study, although the majority of patients in the human lipidomic dataset used in validation were female. These participants were undergoing bariatric surgery, thereby making the matching plasma and liver lipidomics possible, and had BMIs 40-50, which further restricts the extrapolation of these results. Additionally, measuring the plasma lipids represented in the ratios identified in the study is not part of routine clinical care, which prevents the retrospective examination of existing larger-scale or population datasets. Nonetheless, Parker and colleagues provide multiple avenues for future novel cell biology studies, and their data underscore how much we have to learn about the proteasome, its role in lipid metabolism as well as the roles of its moonlighting chaperone and component proteins. 
